In lung cancer, early diagnosis is the strongest predictor of survival and stage 1 is detected in only 15% of patients incidentally. To improve the outcomes, screening for cancer in the early stage in high-risk groups is a promising strategy. Aim The aim of this study was to assess the attitudes and knowledge of lung cancer screening practice in chest physicians. Patients and methods A self-administered questionnaire was distributed to a total of 75 chest physicians and the data were analysed.
Introduction
Lung cancer is the leading cause of cancer deaths (23-11% of total cancer deaths among men and women) [1] [2] . In Egypt, it occupied the third or fourth ranks representing 5-7% of cancers according to the national registry program [3] .
Despite therapeutic advances, the overall lung cancer 5-year survival rates over the past 30 years is ∼15% for all stages combined [4] . Only one-third of patients are identified at an early stage because of the lack of effective screening tools and most patients do not seek medical advice until the advanced stages when treatment is of limited success and when survival is poor [5] .
There is debate about the utility of screening patients for lung cancer [6] and no randomized, controlled trial has demonstrated that screening with chest radiograph or sputum cytology reduces mortality from lung cancer [7] . Owing to lack of evidence, major expert groups have not recommended screening for lung cancer in asymptomatic individuals, even those with heavy or long-term smoking histories [8] [9] [10] .
The Japan Lung Cancer Society has proposed practical guidelines to determine the high-risk group. All participants, aged less than 40 years, should be asked about their smoking history, chest symptoms within the past 6 months, and history of previous regular annual check-ups for lung cancer mass screening [11] .
Meanwhile, the American Society of Clinical Oncology in 2012 suggested that annual screening with low-dose computed tomography (LDCT) should be offered, but only in settings that can deliver comprehensive care. They added that for individuals with less risk (<30 pack-years smoking, <55 years old, or quit smoking >15 years), CT screening should not be performed [12] .
Aim
The aim of the study were as follows:
(1) Update our knowledge about lung cancer screening among Egyptian chest physicians. (2) Reassess the physician practice and beliefs about the effectiveness of screening tests, in the past 12 months. (3) Assess the physicians' intentions to screen highrisk groups for lung cancer.
Patients and methods
A total of 75 chest physicians were included, through self-administered questionnaire. The survey included physicians representing all areas of Egypt, urban and rural, Upper Egypt, Cairo and Delta (North Egypt), in Primary Care Units, Chest hospitals, General Hospitals and University Hospitals.
Questionnaire items
In this study the National Survey of Primary Care Physicians' Cancer Screening Recommendations and Practices Colorectal and Lung Cancer Screening Questionnaire were used [13] .
Statistical analysis
Data were presented as number and percentage. Analyses were done using SPSS, version 16 (SPSS Inc., Chicago, Illinois, USA).
Results
This self-administered questionnaire was distributed to 75 chest physicians in Egypt; 62.5% are working in university hospitals, 11.3% are working in large medical and healthcare centres and the rest are working in physician-owned practice facilities ( Fig. 1 ). Figure 2 illustrates that the participants believe that LDCT is the most effective screening test in reducing cancer mortality in never smokers, former smokers and current smokers (70%, 61.3 and 85%, respectively). The chest radiology (CXR) is believed to be somewhat effective (57.5, 50 and 51.2% in never, former and current smokers, respectively). The sputum cytology is believed to be not effective in all groups.
The recommended screening tests in different suspected groups are analysed in Table 1 . It shows that more than half of the doctors (52.5%) think that screening is not recommended for healthy 50-year-old nonsmokers. In former smokers (quit smoking >1 year) and current smokers, 31.3 and 62.5% of doctors believe that LDCT has a role in screening lung cancer. Sputum cytology is the least ordered test in all patient groups (1.3-6.3% of doctors).
As regards the doctor's practice in the past 12 months for lung cancer screening, 68.8 and 43.8% initiated a discussion about the risks and benefits of screening. Then 60% of doctors referred their patients to CXR and 21.3% ordered an LDCT ( Table 2 ).
Figure 1
Categories that best describe the main primary care practice location for the included physicians (%).
In the past 12 months, doctors say that only 40% of patients asked about lung cancer screening. More than 60% of doctors asked about their smoking behaviour (Table 3) .
Regarding the availability of lung cancer screening in the doctors practice areas, 90% of doctors have LDCT available in their geographic areas. However, 82.5% do not provide Data are expressed as percentage. lung cancer screening program for any risk group (Fig. 3 ).
Discussion
In this study, we evaluated the chest physician practice in lung cancer screening and whether they consider CXR, sputum cytology, or LDCT as effective tools in asymptomatic high-risk patients. Many authors addressed that there is a gap between clinical practice and the need for early detection of lung cancer [14] .
The results of this study showed that doctors believe that LDCT is a very effective screening test in reducing cancer mortality in never smokers, former smokers and current smokers (70%, 61.3 and 85%, respectively) followed by CXR (57.5, 50 and 51.2% somewhat effective in never, former and current smokers). The role of sputum cytology is believed to be not effective in all groups. It is believed that LDCT screening of the high-risk group can reduce lung cancer death [14] . To optimize the balance of benefits and harms of radiation at the population level, recent guidelines recommend that LDCT screening be conducted in 'effective screening settings'. In 2015, the American Thoracic Society issued a statement composed of nine points designed to ensure safe, effective screening by LDCT [15] .
The Japan Lung Cancer Society emphasised the role of CXR and recommended that all high-risk patients receive direct chest radiography or fluoroscopic chest radiography (posteroanterior view). The radiograph film should be double checked by two examiners [11] . A recent study stated that CXR detects new cancer less than six times than sputum cytology. They added that these results do not justify recommending CXR or sputum cytology for lung cancer screening on a large scale [16] .
Also, the current study showed that 62.5% of physicians believe that asymptomatic, more than 50 years old and current smokers (>20 pack-years) need screening with LDCT for lung cancer. The Chest/ American Society of Clinical Oncology guidelines suggest that screening should be offered to individuals aged 55-74 years, smokers (>15 years, Table 3 During the past 12 months, patients attitudes to lung cancer screening and smoking ≥30 pack-years), without comorbidities that limit life expectancy [17] .
In the past year, 68.8 and 43.8% of the included chest physicians initiated a discussion about the risks and benefits of lung cancer screening or discussed with high-risk patients the results of LDCT. Then 60% of doctors referred their patients to CXR and 21.3% ordered LDCT. It is agreed that any successful program should be performed as early as possible in primary care units. Educational programs that emphasize LDCT as a screening tool may improve quality of care and outcomes for individuals at high risk for lung cancer [18] .
One promising strategy may be to encourage doctors to offer LDCT screening option as part of the smoking cessation programs [19] .
The majority of chest physicians (90%) said that they have LDCT available in their geographic areas. However, 82.5% do not provide lung cancer screening program for any risk group. The awareness of screening programs ranged from 0 to 48.4%. An earlier survey in 2014 showed that only 21.7% of chest physicians in Egypt order an LDCT and 19.5% ordered CXR as lung cancer screening tests for asymptomatic patients, even though they are recommended by expert groups. It was recommended that chest physicians and patients need more information about the guidelines, benefits and costs of lung cancer screening to avoid overuse or underuse of lung cancer screening [20] . Some programs have tasked primary care providers with shared decision-making at the time of referral for LDCT screening [21] . The advantage is that patients will have a prior relationship with the physician that may facilitate further discussions. Clinicians should be aware of the benefits and harms of LDCT screening and how they vary depending on a patient's risk factors and comorbidities [18] . The discrepancy between lung cancer screening evidence and actual practice that this study documents provides important context for considering the continuous education of all heathcare providers.
A limitation of this study was that the used selfadministered questionnaire for lung cancer screening was not validated with the patient's medical records. The survey module was relatively brief, and did not include detailed questions about specific characteristics of patients for whom physicians ordered lung cancer screening tests.
Conclusion
In Egypt, chest physicians believe that screening by LDCT for the high-risk group of lung cancer is evidence based in most of the programmes. Still most of them do not follow any screening programme for risk groups. Education for chest physicians as well as shared decision-making for eligible high-risk groups may increase the awareness, accuracy, and efficacy of lung cancer screening.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest
